Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells

Leukemia

Volumn 11, Issue 6, 1997, Pages 811-819

  De Fabritiis, P ^a,e   Skorski, T ^c   De Propris, M S ^a   Paggi, M G ^b   Nieborowska Skorska, M ^c   Lisci, A ^a   Buffolino, S ^a   Campbell, K ^c   Geiser, T ^d   Calabretta, B ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d ILLUMINA INC   (United States)

^e Institute of Haematology   (Italy)

Author keywords

bcr abl oligonucleotides; CD34+ cells; Chronic myelogenous leukaemia; p210(bcr abl)

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CD34 ANTIGEN; OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 16944366178     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400664     Document Type: Article

References (27)

1. Calabretta B. Inhibition of proto-oncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Res 1991; 51: 4505-1510.
2. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-99.
3. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogeneous leukemia. Nature 1985; 315: 550-554.
4. Gale RP, Canaani E. An 8 Kb abl RNA transcript in chronic myelogenous leukemia. Proc Natl Acad Sci USA 1984; 81: 5648-5654.
5. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37: 1035-1040.
6. Daley GA, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the p-120 bcr-abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
7. Heisterkamp N, Jenster G, Ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukemia in bcr/abl transgenic mice. Nature 1990; 344: 251-253.
8. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B. Selective inhibition of leukemia cell proliferation by bcr-abl antisense oligodeoxynucleotides. Science 1991; 253: 562-565.
9. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P. Cell growth in mice by bcr-abl antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1994; 31: 4504-4508.
10. Skorski T, Szczylik C, Malaguarnera L, Calabretta B. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides. Folia Histochem Cytobiol 1991; 29: 85-89.
11. Mahon FX, Belloc F, Reiffers J. Antisense oligomers in chronic myeloid leukemia (letter). Lancet 1993; 341: 566.
12. Kirkland MA, O'Brian SG, McDonald C, Davidson RJ, Cross NCP, Goldman JM. BCR-ABL antisense purging in chronic myeloid leukemia (letter). Lancet 1993; 342: 614.
13. de Fabritiis P, Dowding C, Bungey J, Chase A, Angus G, Szydlo R, Goldman JM. Phenotypic characterization of normal and CML CD34-positive cells: only the most primitive CML progenitors include Ph-neg cells. Leuk Lymphoma 1993; 11: 51-61.
14. Campbell ML, Li W, Arlinghous PB. P210 bcr-abl is complexed to p160 bcr and ph-P53 protein in K562 cells. Oncogene 1990; 5: 773-780.
15. Dhut S, Champlin T, Young B. BCR-ABL and ABL proteins: biochemical characterization and localization. Leukemia 1990; 4: 745-753.
16. de Fabritiis P, Amadori S, Calabretta B, Mandelli F. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transplant 1993; 12: 261-265.
17. de Fabritiis P, Amadori S, Petti MC, Mancini M, Montefusco E, Picardi A, Geiser T, Campbell K, Calabretta B, Mandelli F. In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent hematological reconstitution after autologous bone marrow transplantation. Leukemia 1995; 9: 662-664.
18. Luger SM, Ratajczak MZ, Stadtmauer EA, Mangan P, Magee D, Silberstein L, Edelstein M, Nowell P, Gewirtz AM. Autografting for chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotide purged bone marrow. Blood 1994; 84 (Suppl. 1) Abstr. 591.
19. Chasty R, Whetton A, Lucas G. A comparison of the effect of bcr/abl breakpoint specific phosphorothioate oligodeoxynucleotides on colony formation by bcr/abl positive and negative CD34 enriched mononuclear cell population. Leukemia Res 1996; 20: 391-395.
20. Vaerman JL, Lammineur C, Moureau P, Lewalle P, Deldime F, Blumenfeld M, Martial P. BCR-ABL oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism, Blood 1995; 86: 3891-3896.
21. Bergan R, Connell Y, Fahmy B, Kyle E, Neckers L. Aptameric inhibition of p210 bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res 1994; 22: 2150-2155.
22. Krieg AM, Yi A-K, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretsky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-549.
23. Martial P, Lewalle P, Taji AS, Philippe M, Larondelle Y, Vaerman JL, Wildmann C, Goldman JM, Michaux JL. Retrovirally transduced antisense sequences stably suppress p210bcr-abl expression and inhibit the proliferalion of BCR-ABL-containing cell lines. Blood 1993; 81: 502-509.
24. Bedi A, Zehanbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by bcr-abl in chronic myeloid leukemia. Blood 1994; 83: 2038-2044.
25. Zhao Q, Waldschidt T, Fisher E, Herrera CJ, Krieg AM. Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursor. Blood 1994; 84: 3660-3666.
26. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11: 1475-1489.
27. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak M, Szczylik C, Zon G, Arlinghaus RB, Gewirtz A, Perussia B, Calabretta B. p210 GAP requirement in normal and malignant human hematopoiesis. J Exp Med 1993; 178: 1923-1933.